Blog
RSS FeedPosted by Michael Wonder on 25 May 2022
Bausch + Lomb receives Health Canada approval of Lumify redness reliever eye drops
24 May 2022 - Lumify is Canada's first and only over the counter eye drop with low dose brimonidine for ...
Posted by Michael Wonder on 18 May 2022
Alnylam announces Health Canada authorisation of Oxlumo (lumasiran), the first and only treatment for primary hyperoxaluria type 1 to lower urinary oxalate levels in paediatric and adult patients
18 May 2022 - Authorization based on two pivotal Phase 3 trials, ILLUMINATE-A and ILLUMINATE-B; showing significant reduction in urinary ...
Posted by Michael Wonder on 05 May 2022
Health Canada approves Ipsen's Cabometyx (cabozantinib) for patients with previously treated radioactive iodine refractory or ineligible differentiated thyroid cancer
Pivotal Phase 3 trial data showed Cabometyx demonstrated a significant improvement in progression-free survival. ...
Posted by Michael Wonder on 27 Apr 2022
Health Canada approves Vraylar (cariprazine) for the treatment of bipolar l disorder and schizophrenia in adults
27 April 2022 - Vraylar is a new atypical antipsychotic medication with partial agonist activity at central dopamine D3 receptors ...
Posted by Michael Wonder on 20 Apr 2022
Otsuka announces Health Canada approval of Tavneos (avacopan) for ANCA associated vasculitis
20 April 2022 - Launch is expected in Canada in the fourth quarter of 2022. ...
Posted by Michael Wonder on 19 Apr 2022
Health Canada approves Keytruda (pembrolizumab) for the treatment of adult patients with high risk early stage triple negative breast cancer in combination with chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery
18 April 2022 - Approval Based on Data from Phase 3 KEYNOTE-522 Trial ...
Posted by Michael Wonder on 15 Apr 2022
Evusheld receives Health Canada approval for pre-exposure prophylaxis (prevention) of COVID-19 in immune-compromised individuals
14 April 2022 - Evusheld is the first long-acting antibody combination to receive Health Canada authorisation for the prevention of ...
Posted by Michael Wonder on 12 Apr 2022
Health Canada has approved Zeposia (ozanimod), an oral treatment for adults with moderately to severely active ulcerative colitis
12 April 2022 - Zeposia is the first and only S1P receptor modulating agent approved for the treatment of ulcerative ...
Posted by Michael Wonder on 12 Apr 2022
Jardiance (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction
12 April 2022 - Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in ...
Posted by Michael Wonder on 11 Apr 2022
Health Canada approves Gardasil 9 (human papillomavirus 9 valent vaccine, recombinant) for the prevention of oropharyngeal and other head and neck cancers
11 April 2022 - Gardasil 9 is the first vaccine in Canada approved for the prevention of HPV related oropharyngeal ...
Posted by Michael Wonder on 05 Apr 2022
Janssen announces Health Canada approval of Rybrevant (amivantamab), the first and only targeted treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
4 April 2022 - Targeting both cancer driving and resistance mechanism pathways, Rybrevant offers a unique treatment approach for an ...
Posted by Michael Wonder on 29 Mar 2022
Seqirus receives Health Canada approval for expanded age indication of its cell-based quadrivalent influenza vaccine for people as young as six months
28 March 2022 - Seqirus announced today that it has received Health Canada approval of Flucelvax Quad (influenza vaccine), its cell-based ...
Posted by Michael Wonder on 28 Mar 2022
Dupixent (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation
28 March 2022 - This is the sixth indication for Dupixent in Canada, its second in asthma, and its second in ...
Posted by Michael Wonder on 28 Mar 2022
Health Canada grants marketing authorisation for Kalydeco (ivacaftor) for patients with cystic fibrosis between the ages of 4 months and 18 years with the R117H mutation in the CFTR gene
25 March 2022 - CNW/ - Vertex Pharmaceuticals Canada today announced that Health Canada has granted marketing authorisation for the ...
Posted by Michael Wonder on 20 Mar 2022
AbbVie expands immunology portfolio in Canada as Health Canada approves Skyrizi (risankizumab) for the treatment of adults with active psoriatic arthritis
17 March 2022 - Approval supported by data from two Phase 3 studies evaluating Skyrizi in psoriatic arthritis patients, KEEPsAKE-1 ...